deferoxamine has been researched along with Angiogenesis, Pathologic in 26 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "However, the role of PPARδ in colon cancer cells in a hypoxic tumor microenvironment is not fully understood." | 1.40 | PPARδ deficiency disrupts hypoxia-mediated tumorigenic potential of colon cancer cells. ( Hwang, DH; Jeong, E; Koo, JE; Kwak, MK; Lee, JY; Yeon, SH, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (11.54) | 18.2507 |
| 2000's | 5 (19.23) | 29.6817 |
| 2010's | 10 (38.46) | 24.3611 |
| 2020's | 8 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Theriault, JR | 1 |
| Felts, AS | 1 |
| Bates, BS | 1 |
| Perez, JR | 1 |
| Palmer, M | 1 |
| Gilbert, SR | 1 |
| Dawson, ES | 1 |
| Engers, JL | 1 |
| Lindsley, CW | 1 |
| Emmitte, KA | 1 |
| Lee, YN | 1 |
| Wang, HH | 1 |
| Su, CH | 1 |
| Lee, HI | 1 |
| Chou, YH | 1 |
| Hsieh, CL | 1 |
| Liu, WT | 1 |
| Shu, KT | 1 |
| Chang, KT | 1 |
| Yeh, HI | 1 |
| Wu, YJ | 1 |
| Bian, J | 1 |
| Bao, L | 1 |
| Gao, X | 1 |
| Wen, X | 1 |
| Zhang, Q | 1 |
| Huang, J | 1 |
| Xiong, Z | 1 |
| Hong, FF | 1 |
| Ge, Z | 1 |
| Cui, W | 1 |
| Li, N | 1 |
| Zhan, A | 1 |
| Jiang, Y | 1 |
| Liu, H | 1 |
| Kuehlmann, B | 1 |
| Wan, DC | 1 |
| Gurtner, GC | 3 |
| Oranges, CM | 1 |
| Giordano, S | 1 |
| di Summa, PG | 1 |
| Haug, M | 1 |
| Schaefer, DJ | 1 |
| Choi, J | 2 |
| Chen, S | 1 |
| Li, Y | 1 |
| Yang, Z | 1 |
| Krajcovicova, S | 1 |
| Daniskova, A | 1 |
| Bendova, K | 1 |
| Novy, Z | 1 |
| Soural, M | 1 |
| Petrik, M | 1 |
| Hou, Z | 1 |
| Nie, C | 1 |
| Si, Z | 1 |
| Ma, Y | 1 |
| Jeong, E | 1 |
| Koo, JE | 1 |
| Yeon, SH | 1 |
| Kwak, MK | 1 |
| Hwang, DH | 1 |
| Lee, JY | 1 |
| Donneys, A | 2 |
| Nelson, NS | 1 |
| Page, EE | 1 |
| Deshpande, SS | 2 |
| Felice, PA | 1 |
| Tchanque-Fossuo, CN | 2 |
| Spiegel, JP | 1 |
| Buchman, SR | 2 |
| Jung, KO | 1 |
| Youn, H | 1 |
| Lee, CH | 1 |
| Kang, KW | 1 |
| Chung, JK | 1 |
| Puppo, M | 1 |
| Battaglia, F | 1 |
| Ottaviano, C | 1 |
| Delfino, S | 1 |
| Ribatti, D | 1 |
| Varesio, L | 1 |
| Bosco, MC | 1 |
| Nakamura, M | 1 |
| Bodily, JM | 1 |
| Beglin, M | 1 |
| Kyo, S | 1 |
| Inoue, M | 1 |
| Laimins, LA | 1 |
| Thangarajah, H | 2 |
| Yao, D | 2 |
| Chang, EI | 2 |
| Shi, Y | 2 |
| Jazayeri, L | 1 |
| Vial, IN | 2 |
| Galiano, RD | 2 |
| Du, XL | 1 |
| Grogan, R | 1 |
| Galvez, MG | 2 |
| Januszyk, M | 2 |
| Brownlee, M | 2 |
| Grogan, RH | 1 |
| Glotzbach, JP | 1 |
| Wong, VW | 1 |
| Pourgholami, MH | 1 |
| Cai, ZY | 1 |
| Badar, S | 1 |
| Wangoo, K | 1 |
| Poruchynsky, MS | 1 |
| Morris, DL | 1 |
| Ruggiero, A | 1 |
| Villa, CH | 1 |
| Holland, JP | 1 |
| Sprinkle, SR | 1 |
| May, C | 1 |
| Lewis, JS | 1 |
| Scheinberg, DA | 1 |
| McDevitt, MR | 1 |
| Weiss, DM | 1 |
| Ahsan, S | 1 |
| Sarhaddi, D | 1 |
| Levi, B | 1 |
| Goldstein, SA | 1 |
| Zgouras, D | 1 |
| Wächtershäuser, A | 1 |
| Frings, D | 1 |
| Stein, J | 1 |
| Le, NT | 1 |
| Richardson, DR | 1 |
| Gleadle, JM | 1 |
| Ebert, BL | 1 |
| Firth, JD | 1 |
| Ratcliffe, PJ | 1 |
| Im, MJ | 1 |
| Beil, RJ | 1 |
| Wong, L | 1 |
| Angel, MF | 1 |
| Manson, PN | 1 |
| Kitazono, M | 1 |
| Takebayashi, Y | 1 |
| Ishitsuka, K | 1 |
| Takao, S | 1 |
| Tani, A | 1 |
| Furukawa, T | 1 |
| Miyadera, K | 1 |
| Yamada, Y | 1 |
| Aikou, T | 1 |
| Akiyama, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers[NCT03137966] | Phase 2 | 174 participants (Anticipated) | Interventional | 2022-12-30 | Not yet recruiting | ||
| Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes[NCT03085771] | Phase 2 | 30 participants (Anticipated) | Interventional | 2017-01-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
26 other studies available for deferoxamine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Discovery of a new molecular probe ML228: an activator of the hypoxia inducible factor (HIF) pathway.
Topics: Animals; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Design; Humans; Hypoxia; | 2012 |
Deferoxamine accelerates endothelial progenitor cell senescence and compromises angiogenesis.
Topics: Aging; Animals; Cell Proliferation; Cells, Cultured; Cellular Senescence; Deferoxamine; Endothelial | 2021 |
Bacteria-engineered porous sponge for hemostasis and vascularization.
Topics: Animals; Bacteria; Bandages; Biocompatible Materials; Cells, Cultured; Cellulose; Deferoxamine; Hemo | 2022 |
A novel matrix metalloproteinases-cleavable hydrogel loading deferoxamine accelerates diabetic wound healing.
Topics: Animals; Deferoxamine; Diabetes Mellitus, Experimental; Diabetic Foot; Hydrogels; Matrix Metalloprot | 2022 |
Discussion: Recipient-Site Preconditioning with Deferoxamine Increases Fat-Graft Survival by Inducing VEGF and Neovascularization in a Rat Model.
Topics: Animals; Deferoxamine; Graft Survival; Neovascularization, Pathologic; Neovascularization, Physiolog | 2019 |
Recipient-Site Preconditioning with Deferoxamine Increases Fat Graft Survival by Inducing VEGF and Neovascularization in a Rat Model.
Topics: Animals; Deferoxamine; Graft Survival; Neovascularization, Pathologic; Neovascularization, Physiolog | 2020 |
Reply: Recipient-Site Preconditioning with Deferoxamine Increases Fat Graft Survival by Inducing VEGF and Neovascularization in a Rat Model.
Topics: Animals; Deferoxamine; Graft Survival; Neovascularization, Pathologic; Neovascularization, Physiolog | 2020 |
Recipient-Site Preconditioning with Deferoxamine Increases Fat Graft Survival by Inducing VEGF and Neovascularization in a Rat Model.
Topics: Animals; Deferoxamine; Graft Survival; Neovascularization, Pathologic; Neovascularization, Physiolog | 2020 |
Reply: Recipient-Site Preconditioning with Deferoxamine Increases Fat Graft Survival by Inducing VEGF and Neovascularization in a Rat Model.
Topics: Animals; Deferoxamine; Graft Survival; Neovascularization, Pathologic; Neovascularization, Physiolog | 2020 |
[
Topics: Animals; Cell Line, Tumor; Deferoxamine; Female; Gallium Radioisotopes; Glioblastoma; Humans; Integr | 2021 |
Deferoxamine enhances neovascularization and accelerates wound healing in diabetic rats via the accumulation of hypoxia-inducible factor-1α.
Topics: Animals; Blotting, Western; Cell Proliferation; Cells, Cultured; Deferoxamine; Diabetes Mellitus, Ex | 2013 |
Deferoxamine enhances neovascularization and accelerates wound healing in diabetic rats via the accumulation of hypoxia-inducible factor-1α.
Topics: Animals; Blotting, Western; Cell Proliferation; Cells, Cultured; Deferoxamine; Diabetes Mellitus, Ex | 2013 |
Deferoxamine enhances neovascularization and accelerates wound healing in diabetic rats via the accumulation of hypoxia-inducible factor-1α.
Topics: Animals; Blotting, Western; Cell Proliferation; Cells, Cultured; Deferoxamine; Diabetes Mellitus, Ex | 2013 |
Deferoxamine enhances neovascularization and accelerates wound healing in diabetic rats via the accumulation of hypoxia-inducible factor-1α.
Topics: Animals; Blotting, Western; Cell Proliferation; Cells, Cultured; Deferoxamine; Diabetes Mellitus, Ex | 2013 |
PPARδ deficiency disrupts hypoxia-mediated tumorigenic potential of colon cancer cells.
Topics: Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colon; Colonic Neoplasms; Deferox | 2014 |
Targeting angiogenesis as a therapeutic means to reinforce osteocyte survival and prevent nonunions in the aftermath of radiotherapy.
Topics: Analysis of Variance; Animals; Biopsy, Needle; Cell Survival; Cells, Cultured; Deferoxamine; Disease | 2015 |
Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells.
Topics: 3T3 Cells; Animals; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Deferoxamine; Ephrin-A | 2017 |
Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cell Hypoxia; Cell Lin | 2008 |
Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses.
Topics: Cell Hypoxia; Cell Line; Deferoxamine; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Ke | 2009 |
The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues.
Topics: Animals; Cells, Cultured; Deferoxamine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus | 2009 |
HIF-1alpha dysfunction in diabetes.
Topics: Animals; Deferoxamine; Diabetes Mellitus; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit | 2010 |
Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole.
Topics: Albendazole; Angiogenesis Inhibitors; Animals; Cell Hypoxia; Cell Line, Tumor; Deferoxamine; Dose-Re | 2010 |
Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes.
Topics: Actinium; Adenocarcinoma; Animals; Cell Line, Tumor; Colonic Neoplasms; Deferoxamine; Heterocyclic C | 2010 |
Localized deferoxamine injection augments vascularity and improves bony union in pathologic fracture healing after radiotherapy.
Topics: Animals; Cells, Cultured; Deferoxamine; Fracture Healing; Humans; Neovascularization, Pathologic; Ra | 2013 |
Butyrate impairs intestinal tumor cell-induced angiogenesis by inhibiting HIF-1alpha nuclear translocation.
Topics: Active Transport, Cell Nucleus; Butyrates; Caco-2 Cells; Cell Nucleus; Cells, Cultured; Culture Medi | 2003 |
Competing pathways of iron chelation: angiogenesis or anti-tumor activity: targeting different molecules to induce specific effects.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Cycle; Cell Division; Cell Line, Tumor; Chelati | 2004 |
Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents.
Topics: Angiogenesis Inducing Agents; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line; Chelating Agents; | 1995 |
Effects of sympathetic denervation and oxygen free radicals on neovascularization in skin flaps.
Topics: Allopurinol; Animals; Deferoxamine; Female; Graft Survival; Neovascularization, Pathologic; Rats; Ra | 1993 |
Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase.
Topics: Angiogenesis Inducing Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Hypoxia; Cobalt; Deferoxamin | 1998 |